American Express Co. (0R3C)
London Exchange · UK · prices in USD · close of 22 Oct 2026
Key indicators
| Last close | USD 322.00 |
|---|---|
| 52-week range | 284.82 – 390.48 |
| Return, 1 month / 3 months | +4.9% / −7.1% |
| Return, 1 year / 3 years | −7.8% / +130.2% |
| Trend | Below its 200-day average |
| RSI (14) | 58 |
| Volatility (1 year) | 26.4% |
| Worst drawdown (1 year) | -24.0% |
| Average daily value traded | 0.97M USD |
| Dividend yield | 0.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
American Express is a payments and financial services company based in the United States. It issues charge and credit cards to consumers and businesses, runs a card network that processes transactions for merchants, and provides travel and expense management services. Its customers include individual cardholders, small businesses, large corporations and merchants that accept its cards, and it earns much of its revenue from card fees, merchant discount fees and lending interest.
American Express Co. trades under the code 0R3C on the London Exchange in UK, with its price quoted in US dollars (USD). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
American Express Co. (0R3C) trades on the London Exchange in UK. It last closed at USD 322.00 on 22 October 2026.
Its price-based Market X-Ray is 45 out of 100 (a weak price profile), ranking 2,344 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 7.8% and over the last three months it fell 7.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 45 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -1.7% | ||
| From 52-week high | -16.5% | ||
| Momentum | 35 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -7.1% | ||
| 6-month return | -3.0% | ||
| 12-month return, skipping the last month | -12.1% | ||
| Stability (higher is calmer) | 67 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 26.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -24.0% | ||
| Liquidity | 53 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.97M USD | ||
| Zero-volume days | 1.7% | ||
| Income | 7 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.3% | ||
| Years with dividends | 4 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Income: Dividend is small or irregular.
Returns
| 1 week | +2.7% |
|---|---|
| 1 month | +4.9% |
| 3 months | −7.1% |
| 6 months | −3.0% |
| 1 year | −7.8% |
| 3 years | +130.2% |
| 5 years | +79.8% |
Signals
| 50-day / 200-day average | 319.76 / 327.70 |
|---|---|
| Golden / death cross (60 days) | Death, 21 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 7.10 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 31 Dec 2025 | USD 0.8200 |
| 9 Oct 2025 | USD 0.8200 |
| 2 Jul 2025 | USD 0.8200 |
| 3 Apr 2025 | USD 0.8200 |
| 2 Jan 2025 | USD 0.7000 |
| 3 Oct 2024 | USD 0.7000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.